Zantac 75 Ad Comparison to Prilosec OTC Needs Revision, NAD Concludes
This article was originally published in The Tan Sheet
Executive Summary
Ad claims for Pfizer's Zantac 75 that compare the H2 antagonist to Procter & Gamble's Prilosec OTC should be modified so consumers understand the heartburn remedies have different indications, the National Advertising Division of the Council for Better Business Bureaus concludes following a recent inquiry
You may also be interested in...
Pepto-Bismol Cherry Flavor Marks First Line Extension In A Decade
The debut of cherry-flavored Pepto-Bismol represents the first time the taste of the well-known stomach remedy has been changed in the product's hundred-year history, Procter & Gamble says
Prilosec OTC Soothes P&G First Quarter Forecast As Early Shipments Rollout
Stronger than expected initial orders for Prilosec OTC are responsible in part for Procter & Gamble's increase in its first quarter earnings guidance for fiscal year 2004
Prilosec OTC Heats Up Heartburn Sector; Competitors Set Sights On Launch
Pfizer has initiated a competitive advertising campaign against Prilosec as Procter & Gamble gears up to introduce the OTC version of the proton pump inhibitor this quarter